6 Results for "

H3K4 demethylation

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "H3K4 demethylation" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-138830
CAS No.: 1818252-53-7
Purity:  99.81%
Target:  

Histone Demethylase

Research Areas:  

Neurological Disease

TAK-418 is an orally active, blood-brain barrier-penetrant LSD1 inhibitor with a human IC50 of 2.9 nM. TAK-418 irreversibly inhibits LSD1 by forming a compact flavin-FAD adduct with the catalytic domain FAD, blocking the demethylation of H3K4me1/2 and H3K9me1/2 without disrupting the LSD1-GFI1B interaction. TAK-418 restores normally dysregulated brain gene expression and DNA methylation, increases H3K4me1/2/3 and H3K9me2 at the Ucp2 locus, and induces Ucp2 mRNA expression. TAK-418 rescues defective H3K4 histone modifications, normalizes adult neurogenesis, and improves recognition memory, social behavior, and cognition in rodent models. TAK-418 can be used in research related to neurodevelopmental disorders, Alzheimer's disease, and autism spectrum disorders .
loading...
    loading...
Cat. No.: HY-149213
CAS No.: 4734-59-2
Purity:  99.20%
Synonyms: J54; J3-54
Research Areas:  

Cancer

LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .
loading...
    loading...
Cat. No.: HY-173590
CAS No.: 2455469-18-6
Target:  

Histone Demethylase

Research Areas:  

Cancer

AW4 is a LSD1 inhibitor. AW4 inhibits LSD1 ΔTTAS activity in H3K4me2 demethylation assays. AW4 can be used for research of drug resistance .
loading...
    loading...
Cat. No.: HY-168086
CAS No.: 2992690-04-5
LSD1-IN-35 (Compound Z-1) is a selective LSD1 Inhibitor (IC50: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1/2. LSD1-IN-35 is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction .
loading...
    loading...
Cat. No.: HY-138830B
CAS No.: 1818252-52-6
Target:  

Histone Demethylase

Research Areas:  

Neurological Disease

TAK-418 free base is an orally active, blood-brain barrier-penetrant LSD1 inhibitor with a human IC50 of 2.9 nM. TAK-418 free base irreversibly inhibits LSD1 by forming a compact flavin-FAD adduct with the catalytic domain FAD, blocking the demethylation of H3K4me1/2 and H3K9me1/2 without disrupting the LSD1-GFI1B interaction. TAK-418 free base restores normally dysregulated brain gene expression and DNA methylation, increases H3K4me1/2/3 and H3K9me2 at the Ucp2 locus, and induces Ucp2 mRNA expression. TAK-418 free base rescues defective H3K4 histone modifications, normalizes adult neurogenesis, and improves recognition memory, social behavior, and cognition in rodent models. TAK-418 free base can be used in research related to neurodevelopmental disorders, Alzheimer's disease, and autism spectrum disorders .
loading...
    loading...
Cat. No.: HY-187092
CAS No.: 1423715-30-3
Target:  

Histone Demethylase

Research Areas:  

Cancer

LSD1-IN-51 is a selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 8.7 nM. LSD1-IN-51 selectively inhibits H3K4me1/2 demethylation by binding to the FAD domain of LSD1, while disrupting the interaction between LSD1 and multiprotein complexes such as HDAC1/2 and CoREST. LSD1-IN-51 can be used for cancer research .
loading...
    loading...